InfuSystem Holdings (INFU) AI Stock Analysis

• Market Cap: $214.88M
• Dividend Yield: N/A
• Average Volume (3M): 212.05K
• Price to Earnings (P/E): 44.4
• Beta (1Y): 1.65
• Revenue Growth: 8.13%
• EPS Growth: 1293.06%
• Country: US
• Employees: 502
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 0.12
• Shares Outstanding: 20,425,964
• 10 Day Avg. Volume: 156,505
• 30 Day Avg. Volume: 212,050
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.75
• Enterprise Value/Revenue: 1.15
• Enterprise Value/Gross Profit: 2.11
• Enterprise Value/Ebitda: 6.77
• 1Y Price Target: $14.33
• Price Target Upside: 49.27% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

• Rating: 70 Outperform
• Price Target: $10.50 ▲(9.38% Upside)

InfuSystem Holdings demonstrates robust financial performance and strategic initiatives, particularly in revenue growth and cash flow. However, high valuation metrics and overbought technical indicators suggest caution. The earnings call and corporate events provide a positive outlook, but challenges in specific segments temper the overall score.

Positive Factors

Revenue Growth and Margin Expansion

Consistent revenue growth and margin expansion indicate strong market demand and effective cost management, enhancing long-term profitability.

Cash Flow Generation

Strong cash flow generation supports financial flexibility and investment capacity, crucial for sustaining growth and competitive positioning.

Credit Agreement Extension

Extending the credit agreement maturity enhances financial stability and operational flexibility, supporting long-term strategic initiatives.

Negative Factors

Lower Revenue Growth Outlook

Reduced revenue growth outlook reflects challenges in key segments, potentially impacting future earnings and market confidence.

Challenges in Wound Care and ChemoMouthpiece

Operational challenges in these segments may hinder revenue diversification and growth, affecting overall business performance.

Restructuring of GE Healthcare Relationship

Restructuring could reduce revenue from GE Healthcare, impacting short-term sales, though it may improve margins longer term.

InfuSystem Holdings Business Overview & Revenue Model

Company Description

InfuSystem Holdings, Inc. (INFU) is a leading provider of infusion pumps and related services, primarily serving the healthcare sector. The company specializes in the rental and sale of infusion pumps, as well as providing a comprehensive suite of services, including maintenance, logistics, and patient support. InfuSystem's core products cater to various medical applications, including pain management, chemotherapy, and antibiotic therapies, making it an essential partner for hospitals, clinics, and home healthcare providers.

How the Company Makes Money

InfuSystem generates revenue through multiple key streams, primarily from the rental and sale of infusion pumps and related equipment. The company charges healthcare facilities for the leasing of their infusion devices, which can include both short-term and long-term contracts. Additionally, InfuSystem earns income through the provision of consumables, such as IV administration sets and related supplies necessary for the operation of their infusion systems. Service agreements, which encompass maintenance, repair, and technical support, also contribute significantly to the company's revenue. Strategic partnerships with healthcare providers and manufacturers further enhance their market reach and service offerings, allowing InfuSystem to secure recurring revenue and build long-term customer relationships.

InfuSystem Holdings Financial Statement Overview

Summary

InfuSystem Holdings shows strong revenue growth and cash flow generation, with a stable gross profit margin. The company has improved its leverage position and return on equity, although profitability margins could be enhanced.

Income Statement

InfuSystem Holdings has demonstrated strong revenue growth, particularly in the TTM period, with a 1.68% increase. The gross profit margin has remained stable around 54.5%, indicating efficient cost management. However, the net profit margin is relatively low at 4.84%, suggesting room for improvement in profitability. The EBIT and EBITDA margins are healthy, reflecting solid operational performance.

Balance Sheet

The company's debt-to-equity ratio has improved over time, currently at 0.56, indicating a balanced approach to leveraging. Return on equity has increased to 12.15% in the TTM period, showcasing better utilization of equity. However, the equity ratio is moderate, suggesting a need for cautious financial management to maintain stability.

Cash Flow

InfuSystem Holdings has shown impressive growth in free cash flow, with a 29.68% increase in the TTM period. The operating cash flow to net income ratio is strong at 1.67, indicating efficient cash generation relative to earnings. The free cash flow to net income ratio of 0.79 suggests effective conversion of earnings into cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	139.89M	134.86M	125.78M	109.91M	102.38M	97.39M
Gross Profit	76.30M	70.40M	63.11M	62.57M	60.20M	58.76M
EBITDA	23.80M	20.03M	16.50M	14.89M	17.15M	22.82M
Net Income	5.07M	2.35M	872.00K	18.00K	1.42M	17.33M
Balance Sheet
Total Assets	100.85M	103.61M	102.92M	99.39M	97.59M	96.99M
Cash, Cash Equivalents and Short-Term Investments	720.00K	527.00K	231.00K	165.00K	186.00K	9.65M
Total Debt	30.45M	28.42M	36.37M	36.92M	36.77M	42.66M
Total Liabilities	46.31M	46.09M	50.61M	51.38M	49.31M	56.24M
Stockholders Equity	54.53M	57.53M	52.30M	48.00M	48.27M	40.75M
Cash Flow
Free Cash Flow	21.06M	2.63M	106.00K	2.44M	1.66M	3.37M
Operating Cash Flow	26.56M	20.46M	11.22M	17.52M	18.32M	20.28M
Investing Cash Flow	-10.47M	-13.24M	-6.73M	-11.48M	-21.32M	-12.16M
Financing Cash Flow	-15.52M	-6.92M	-4.42M	-6.06M	-6.46M	-1.12M

InfuSystem Holdings Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 9.60
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INFU, the sentiment is Positive. The current price of 9.6 is below the 20-day moving average (MA) of 9.82, below the 50-day MA of 10.04, and above the 200-day MA of 7.31, indicating a bullish trend. The MACD of 0.10 indicates Negative momentum. The RSI at 61.87 is Neutral, neither overbought nor oversold. The STOCH value of 82.77 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for INFU.

InfuSystem Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
INFU	―	$214.88M	44.35	9.39%	―	8.13%	1293.06%
UTMD	―	$182.79M	16.56	9.59%	2.08%	-12.35%	―
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SMTI	―	$262.09M	―	-25.78%	―	34.29%	-49.21%
KRMD	―	$182.63M	―	-25.63%	―	19.57%	61.81%
OSUR	―	$204.05M	―	-12.65%	―	-49.35%	-285.61%

InfuSystem Holdings Corporate Events

InfuSystem Holdings Reports Strong 2024 Revenue Growth

InfuSystem Holdings has reported six consecutive years of record revenue, with a compound annual growth rate (CAGR) of 12% in revenue and 11% in adjusted EBITDA. The company generated $134.9 million in total revenue for 2024, with a strong focus on expanding its device solutions and patient services segments. InfuSystem’s strategic partnerships and acquisitions, such as the agreements with Solo-Dex Inc. and Sanara MedTech, highlight its efforts to enhance its market positioning and offer comprehensive solutions in the medical equipment industry. These initiatives are expected to support the company’s growth and provide substantial cash flow, with $20.5 million in cash flow from operations reported for 2024.

The most recent analyst rating on (INFU) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on InfuSystem Holdings stock, see the INFU Stock Forecast page.

InfuSystem Holdings to Join ROTH Healthcare Conference

On September 25, 2025, InfuSystem Holdings, Inc. announced that its CEO, Carrie Lachance, and CFO, Barry Steele, will participate in the 4th Annual ROTH Healthcare Opportunities Conference on October 9, 2025, in New York City. This participation is expected to enhance the company’s visibility and investor engagement, potentially impacting its market positioning and stakeholder relations positively.

The most recent analyst rating on (INFU) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on InfuSystem Holdings stock, see the INFU Stock Forecast page.

InfuSystem Holdings Reports Strong Q2 2025 Results

InfuSystem Holdings, Inc. is a national healthcare service provider that facilitates outpatient care for durable medical equipment manufacturers and healthcare providers, operating primarily in the Patient Services and Device Solutions sectors. In its second quarter of 2025, InfuSystem reported record net revenues of $36.0 million, marking a 7% growth from the previous year, alongside a significant increase in net income by 262% to $2.6 million. The company also achieved an adjusted EBITDA of $8.0 million, reflecting a 32% rise, and expanded its EBITDA margin to 22.3%. Key financial highlights include a 6% increase in Patient Services revenue and an 8% rise in Device Solutions revenue, driven by strategic investments and operational efficiencies. The company also repurchased $3.5 million in stock, enhancing shareholder value. Looking ahead, InfuSystem is focusing on expanding margins and improving profitability, with an updated revenue growth outlook of 6-8% for 2025, while aiming for an adjusted EBITDA margin of 20% or higher. The company remains committed to disciplined execution and long-term value creation for its shareholders.

InfuSystem Holdings Reports Mixed Earnings Call Results

InfuSystem Holdings, Inc. recently held its earnings call, revealing a mixed sentiment. The company reported a strong financial performance with record revenue and margin expansion, yet faced challenges such as a reduced revenue growth outlook and uncertainties in specific business areas. Notably, the focus on operational efficiency and shareholder returns were highlighted as positive aspects.

InfuSystem Holdings to Announce Q2 2025 Results

InfuSystem Holdings, Inc. announced it will release its second quarter 2025 financial results on August 5, 2025, before the market opens. The company will also host a conference call on the same day to discuss the financial results, providing stakeholders with insights into its financial performance and strategic direction.

The most recent analyst rating on (INFU) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on InfuSystem Holdings stock, see the INFU Stock Forecast page.